Delhi Delhi. Shares of Cipla surged nearly 10 per cent on the NSE (National Stock Exchange) after the US Food and Drug Administration classified the pharmaceutical giant's Goa manufacturing facility as 'Voluntary Action Indicated' (VAI).USFDA's VAI A pharmaceutical manufacturing facility is inspected before receiving classification. Although the FDA found some problems during inspections, this means they are not serious enough to warrant formal enforcement action.
In order to proceed with the product approval or other regulatory processes without any hindrance, the company is expected to voluntarily fix these minor deficiencies. Indian stock markets hit similar highs of the day after the opening bell. The stock touched the day's high of Rs 1,560.05 per share on NSE (National Stock Exchange). Shares of Cipla were trading at Rs 1,534.25 per share, up 8.18 per cent, from Rs 116.00 on NSE (National Stock Exchange). per share is equal to.
Cipla announced its consolidated net profit for the quarter ending September 2024 increased by 15.2 per cent to Rs 1303.53 crore compared to net profit of Rs 1131 crore reported in the same quarter last year. Its operating revenue for the July to September 2024 quarter grew 6 per cent year-on-year to Rs 7051 crore, compared to Rs 6678 crore recorded in the same quarter last year.
Comments are closed.